Optimal adjuvant chemotherapy in breast cancer: selection of agents.

about

New Robust and Reproducible Stereological IHC Ki67 Breast Cancer Proliferative Assessment to Replace Traditional Biased Labeling Index.Is adjuvant chemotherapy necessary for patients with microinvasive breast cancer after surgery?

P2860

Q30489246-0E4515DD-A1AC-49B1-BE08-237FA4B3ACED Q36849655-03171778-EC91-4EFD-8824-7CA6AEC220FB

P2860

Optimal adjuvant chemotherapy in breast cancer: selection of agents.

Item

http://www.wikidata.org/entity/Q38235713

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Optimal adjuvant chemotherapy in breast cancer: selection of agents.

@en

type

Item

label

Optimal adjuvant chemotherapy in breast cancer: selection of agents.

@en

prefLabel

Optimal adjuvant chemotherapy in breast cancer: selection of agents.

@en

P1476

Optimal adjuvant chemotherapy in breast cancer: selection of agents.

@en

P2093

Angela Esposito

http://www.w3.org/2001/XMLSchema#string

Carmen Criscitiello

http://www.w3.org/2001/XMLSchema#string

Emanuela Omodeo Salè

http://www.w3.org/2001/XMLSchema#string

P2860

Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial

c-erbB2 and topoisomerase IIalpha protein expression independently predict poor survival in primary human breast cancer: a retrospective study

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

p53, the cellular gatekeeper for growth and division

Molecular portraits of human breast tumours

Cardiac dysfunction in the trastuzumab clinical trials experience

Clinical application of the 70-gene profile: the MINDACT trial

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

P304

605-611

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/17512433.2014.945429

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Giuseppe Curigliano

P577

2014-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25080998

http://www.w3.org/2001/XMLSchema#string

Optimal adjuvant chemotherapy in breast cancer: selection of agents.

about

P2860

P2860

Optimal adjuvant chemotherapy in breast cancer: selection of agents.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698